WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and Adolor Enter into Exclusive Worldwide Collaboration 06 December 2007
Pfizer to Acquire Coley Pharmaceutical Group 16 November 2007
Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function 06 November 2007
Taisho and Pfizer Sign a Letter of Intent for Taisho’s Schizophrenia Drug Candidate 03 November 2007
Pfizer to Appeal German Court Decision in Lipitor Patent Case 30 October 2007
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent 23 October 2007
Pfizer Reports Third-Quarter 2007 Results 19 October 2007
Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care 15 October 2007
Pfizer Launches Independent Biotherapeutics and Bioinnovation Center 05 October 2007
Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer 28 September 2007
First in a New Oral Class of HIV Medicines in 10 Years 24 September 2007
Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug 19 September 2007
Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib 12 September 2007
Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education 06 September 2007
Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death 05 September 2007
Pfizer Names Frank A. D'Amelio Chief Financial Officer 22 August 2007
UK Body Recommends Pfizer's Champix (varenicline) for Smokers 30 May 2007
  • Start
  • Prev
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next
  • End

Business & Industry

  • Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma

Research & Development

  • Candidate found to inhibit malignant melanoma growth
  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA approves first over-the-counter naloxone nasal spray
  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer invests $43 billion to battle cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.